<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">2985088R</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4967</journal-id>
<journal-id journal-id-type="nlm-ta">J Mol Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Mol. Biol.</journal-id>
<journal-title-group>
<journal-title>Journal of molecular biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-2836</issn>
<issn pub-type="epub">1089-8638</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27040397</article-id>
<article-id pub-id-type="pmc">5532804</article-id>
<article-id pub-id-type="doi">10.1016/j.jmb.2016.03.025</article-id>
<article-id pub-id-type="manuscript">NIHMS882911</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>What have we learned from glycosyltransferase knockouts in mice?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Stanley</surname>
<given-names>Pamela</given-names>
</name>
<aff id="A1">Dept. Cell Biology, Albert Einstein College Medicine, New York, NY, 10461</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="FN1">Pamela Stanley, <email>pamela.stanley@einstein.yu.edu</email>, phone: (718) 430-3346, fax: (718) 430-3470</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>14</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>7</month>
<year>2017</year>
</pub-date>
<volume>428</volume>
<issue>16</issue>
<fpage>3166</fpage>
<lpage>3182</lpage>
<!--elocation-id from pubmed: 10.1016/j.jmb.2016.03.025-->
<abstract>
<p id="P1">There are five major classes of glycan including N- and O-glycans, glycosaminoglycans, glycosphingolipids and glycophosphatidylinositol anchors, all expressed at the molecular frontier of each mammalian cell. Numerous biological consequences of altering the expression of mammalian glycans are understood at a mechanistic level, but many more remain to be characterized. Mouse mutants with deleted, defective, or misexpressed genes that encode activities necessary for glycosylation have led the way to identifying key functions of glycans in biology. However, with the advent of exome sequencing, humans with mutations in genes involved in glycosylation are also revealing specific requirements for glycans in mammalian development. The aim of this review is to summarize glycosylation genes that are necessary for mouse embryonic development; pathway-specific glycosylation genes whose deletion leads to postnatal morbidity; and glycosylation genes for which effects are mild, but perturbation of the organism may reveal functional consequences. General strategies for generating and interpreting the phenotype of mice with glycosylation defects are discussed in relation to human congenital disorders of glycosylation (CDG).</p>
</abstract>
<kwd-group>
<kwd>Glycosylation</kwd>
<kwd>glycosyltransferase</kwd>
<kwd>nucleotide sugar</kwd>
<kwd>glycosidase</kwd>
<kwd>mouse mutants</kwd>
<kwd>congenital disorders of glycosylation</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>